An evening of culinary excellence Signature Chefs Auction, Grand Rapids

DATE: Monday, November 6, 2017 | Time: 5:30 PM
ADDRESS: 303 Monroe Avenue NW, Grand Rapids, MI 49503

Join us for our annual gathering of West Michigan’s finest culinary talent in support of the March of Dimes. Held in the Steelcase Ballroom at DeVos Place, you will enjoy tasting the signature dishes of local chefs before taking your seats for the Live Auction and Fund the Mission. We encourage you to bid on one of our unique packages. Raise your paddle and give generously to save babies!

Full Event Details


grand rapids

$162,000 postdoctoral fellowship from the American Cancer Society.

Mike Wilson, PhD, a Department of Obstetrics, Gynecology and Reproductive Biology postdoc in Dr. Ronald Chandler's lab, has been awarded a three-year, $162,000 postdoctoral fellowship from the American Cancer Society. The grant is to start January 1, 2018. Congratulations Mike on this very prestigious award!

Dr. Asgi Fazleabas Awarded University Distinguished Professor Title

Fazleabas Asgi 017 046 0902


Dr. Asgi Fazleabas has been recommended by the MSU Provost and the Board of Trustees to be designated as a University Distinguished Professor. The University Distinguished Professorship is an honor to be held throughout the remaining years of being active at Michigan State University. Select individuals that receive this award have been recognized nationally and internationally for their scholarly achievements. They will have also exemplified superior teaching skills and a distinguished record of public service. Please join us in congratulating Dr. Fazleabas for his success and this impressive accomplishment.


Click Here to View MSU Faculty Memebers Awarded 2017 University Distinguished Professor Title


Tae Hoon Kim, Ph.D. - Recipient of the M. D. Anderson Cancer Center Gynecologic SPORE for Uterine Cancer Career Enhancement Program

th kimEndometrial cancer is the most frequently diagnosed malignancy of the female genital tract in the United States. Hysterectomy is typically the first line therapeutic strategy for endometrial cancer. However, there is an increasing demand for non-surgical treatments for endometrial cancer, especially for women who may encounter surgical complications as well as patients with advanced and recurrent endometrial cancer. The current alternative to surgical management of early stage endometrial neoplasia (complex hyperplasia with atypia and grade 1 cancer) is progesterone (P4) treatment, commonly via the Levonorgestrel-Releasing Intrauterine System (Mirena IUD). However, a number of women have P4 refractory disease. Resistance to P4 treatment is the major hurdle of endometrial cancer. Therefore, identifying the molecular mechanisms of P4-resistance, with the goal of identifying alternative targets for non-surgical therapies is important. Although identification of molecular mechanisms involved in the resistance to P4 is critical to enable effective and personalized therapy discovery and development, the lack of sufficient pre-clinical animal models in translational research of endometrial cancer makes further study more difficult. In this proposal, our central hypothesis is that Mig-6 loss causes endometrial cancer with P4 resistance through activation of AKT/mTOR signaling in epithelial cells and dysregulatiuon of P4 signaling in stromal cells. We will use our P4-resistant and P4-responsive mouse models. The overall objective of this project is to help improve non-surgical approaches for early stage endometrial cancer by identifying alternative targets. 1) We will identify the molecular targets altered in P4 resistance comparing the P4-responsive and resistant mouse model and 2) evaluate the combination treatment of P4 and everolimus (mTOR inhibitor) on endometrial cancer development and progression. We will identify alternative targets for non-surgical therapies for early stage endometrial cancer.

Professor Barbara Luke Sc.D, MPH, is the recipient of over $2.5 million NICHD/NIH Award



rsz lukebarbara2015


The title of her project is "Assisted Reproduction and Child Health: Risk of Birth Defects, Mortality, and Effect on Grade School Performance." Her project began late September of 2016 and will continue on until May 30th of 2021.

The purpose of this study is to evaluate the risk of mortality, birth defects, and effect on grade school performance among children conceived through in vitro fertilization (IVF, the process by which an oocyte is fertilized by semen outside the body) and assisted reproductive technology (ART, all infertility treatments to achieve conception), their siblings, and non-IVF controls. This is the first time children conceived with IVF have been tracked through school age in the United States.


Jae Wook Jeong to Begin His Term As Member of the Pregnancy and Neonatology Study Section


Dr. Jae-Wook Jeong has recently accepted the invitation to serve as a member of the Pregnancy and Neonatology Study Section. Members who are selected demonstrate competence and achievement in their scientific discipline as evidenced by the quality of research accomplishments, publications in scientific journals, and other significant scientific activities, achievements, and honors. Service on a study section requires mature judgement and objectivity as well as the ability to work effectively in a group, qualities the NIH Center for Scientific Review believes Dr. Jeong will bring to this important task. His term will begin on July 1st, 2017 and will end on June 30th, 2021.


Welcome Dr. Jeff MacKeigan to the Obstetrics, Gynecology and Reproductive Biology Department

rsz jeff mackeigan 031016 003


Dr. Jeff MacKeigan, currently an adjunct associate professor at Michigan State University, will join the College of Human Medicine's Department of Obstetrics, Gynecology and Reproductive Biology as a professor with tenure on August 15th. He will be a part of the Global Impact Initiative and will be moving to the Grand Rapids Research Center this fall.

Some of his higlighted research efforts include:

  • Lab investigates the metabolic triad encompassing autophagy, the PI3K-mTOR pathway, and cell metabolism
  • Systems biology approach integrating multiple technologies and multidisciplinary collaborations to study cancer and complex diseases
  • Current NCI funding to develop a computational model of autophagy in KRAS-driven lung cancer
  • Active collaboration with Caryl Sortwell on repositioning kinase inhibitors for treatment of Parkinson’s Disease

Please join us in welcoming Dr. MacKeigan to the department.


Dr. MacKeigan and Research Team Featured in MSU Today - Research Offers New Clues to Rare Genetic Disease


Stacey Missmer Invited to Join World Endometriosis Society Board of Directors.

Dr. Stacey Missmer has been invited to join the World Endometriosis Society (WES) Board of Directors for the 2017-2020 term. The WES Nominations Comittee met on April 18th and unaminously agreed that she would be a great asset to the WES Board in moving their mission forward: to improve the lives of all affeected women and their families. She began her term at the 13th World Congress on Endometriosis in Vancouver, Canada on May 17th and has been selected to be the treasurer. Please join us in congratulating her on this amazing opportunity.